For drug safety teams, AI in pharmacovigilance starts with a volume problem. Once a drug reaches the market, safety information arrives from far more channels than a review team was originally sized for: spontaneous reports, call center notes, partner exchanges, medical literature, and patient conversations online. Every serious case carries a regulatory submission deadline, and every new report could be one more data point in a safety signal that has not yet been recognized.
Manual review absorbs the first pressure with headcount and the second with periodic aggregate analysis. Both approaches cost time.
A Pfizer team that piloted artificial intelligence (AI) for case handling described safety case processing as the strongest cost driver in a pharmaceutical company’s pharmacovigilance (PV) budget.[1] Teams evaluating AI in pharmacovigilance are usually trying to recover that time without weakening the medical judgment that regulators hold them to.
What is AI in pharmacovigilance?
AI in pharmacovigilance is the use of natural language processing (NLP) and machine learning (ML) to automate high-volume drug safety tasks, such as case intake, MedDRA coding, duplicate checks, and narrative drafting, and to score safety signals continuously. Safety physicians still make the final calls on seriousness, causality, and signal validation.
Key Takeaways
- Manual review delays safety work at two points: case processing and periodic signal review.
- AI processes every report on arrival, which removes the queue.
- ML models outperformed ROR and IC in published studies and flagged some signals before label updates.
- EMA holds the marketing authorization holder responsible for validating and documenting AI models.
- Causality, signal validation, and benefit-risk decisions stay with qualified people.
Why Does Manual Pharmacovigilance Review Slow Down Adverse Event Detection?
Manual review delays adverse event detection in two places : case processing and signal detection.
The first delay sits in individual case safety report (ICSR) processing. Each incoming report has to be read, checked for validity, assessed for seriousness, coded to the Medical Dictionary for Regulatory Activities (MedDRA), screened for duplicates, and written up as a narrative. Serious cases move to the front of the queue because their deadlines are short. Non-serious cases wait, even though they can hold the first evidence of an emerging pattern.
The second delay sits in signal detection : When aggregate review runs on a fixed cycle, a cluster forming across reports becomes visible only at the next review. Statistical screening also needs enough reports to cross a threshold, which means a rare event can take several cycles to register. Both are structural limits of a process that depends on people reading every report in sequence.
How Is AI Used in Pharmacovigilance Today?
AI fits best in the high-volume, rules-heavy steps of the safety workflow. AI adverse event detection typically combines natural language processing (NLP), which reads unstructured text, with machine learning (ML) models that classify and score what the NLP extracts.
- Intake and triage : Models read emails, PDFs, and call transcripts, extract the elements that make a case valid, and flag likely serious cases for priority handling. Pfizer's pilot confirmed the feasibility of AI-based technology for extracting data from adverse event source documents and evaluating case validity.
- Coding and duplicate checks : Systems propose MedDRA terms and match incoming reports against existing cases, leaving the reviewer to confirm rather than search.
- Literature and social media screening : The U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) names AI analysis of scientific literature and social media for potential drug safety issues as one example of what it wants to explore through its Emerging Drug Safety Technology Meeting (EDSTM) program.
- Signal scoring : Models rank drug and event combinations continuously, so safety physicians start each review with a prioritized list.
Much of the speed gain from pharmacovigilance automation comes from removing the queue. Every report is processed on arrival, and every new case updates the signal picture immediately instead of waiting for the next scheduled review.
The difference from a traditional review process is clearest side by side:
| Area | Traditional review | AI-powered review |
|---|---|---|
| Report processing | People read each report in sequence | Every report is processed on arrival |
| Signal review timing | Statistical screening runs at fixed intervals | Signal rankings update continuously |
| Data extraction and coding | Manual data entry and MedDRA term search | Automated extraction with suggested MedDRA terms |
| Reviewer focus | Data entry and case processing | Confirming outputs and making medical judgments |
How Does Machine Learning Improve Signal Detection in Pharmacovigilance?
Machine learning can surface safety signals earlier than disproportionality methods because it uses more context than report counts, such as label information and organ-specific features.
Traditional signal detection in pharmacovigilance relies on disproportionality measures such as the reporting odds ratio (ROR) and information component (IC). These compare how often an event is reported with a drug against the background rate in the database. Researchers note that their simple calculation and uniform thresholds, applied regardless of database characteristics, can produce false positives and miss important associations. [3] In the EU, signal management itself follows GVP Module IX.
Machine learning models in pharmacovigilance can work with more context. In a study of the Korea national spontaneous reporting database, researchers built inputs from drug label information and organ-specific and covariate features alongside report counts. A gradient boosting model performed better than ROR and IC and detected more new adverse drug reaction signals for two cancer drugs, nivolumab and docetaxel. The same research group then tested timing with infliximab. Their models flagged four of five pre-specified adverse events in the first year each appeared in the Korean database, earlier than those events were added to the drug’s label. [4]
The infliximab study screened historical data for a single drug, and its authors note that spontaneous reports carry potential selection bias, under-reporting, and duplicate cases. On a shorter window of FDA data, the models did not match their Korean results, although they still outperformed ROR and IC. For AI in pharmacovigilance, the evidence supports ML as a way to surface candidate signals earlier for human evaluation, used alongside established statistical methods.
What Does AI in Pharmacovigilance Look Like Inside a Pharma Company?
In practice, AI for post-market surveillance works as a set of automated steps with defined human checkpoints. A typical division of labor looks like this :
| Workflow stage | What automation handles | What the reviewer decides |
|---|---|---|
| Intake | Extracts patient, reporter, drug, and event details from any source format | Resolves low-confidence extractions |
| Validity and seriousness | Checks minimum criteria and predicts seriousness | Confirms seriousness, especially borderline cases |
| Coding and duplicates | Suggests MedDRA terms and probable duplicate matches | Accepts, edits, or rejects suggestions |
| Narrative and submission | Drafts the case narrative and builds the electronic report | Performs medical review and approves submission |
| Signal review | Scores and ranks emerging drug and event pairs | Validates signals and assesses causality and benefit-risk |
A commercial drug safety AI platform can supply many of these components. What determines results is the work around it: connecting fragmented safety and source systems, validating each model for its specific task, setting confidence thresholds that route uncertain outputs to people, and keeping an audit trail a regulator can follow.
See how your PV workflow compares : Request a PV Workflow Assessment
What Do FDA and EMA Expect From AI in Pharmacovigilance?
Regulators are open to AI in pharmacovigilance, but accountability does not move to the model. FDA is gathering input through its EDSTM program, and EMA expects the marketing authorization holder to validate, monitor, and document model performance.
For pharmacovigilance AI, FDA has opened a dedicated engagement channel. CDER’s EDSTM program gives companies with approved applications, along with academia, contract research organizations, PV vendors, and software developers, a forum for mutual learning, and FDA plans to use what it learns to inform potential regulatory and policy approaches.
In January 2026, FDA and EMA also issued joint Guiding Principles of Good AI Practice in Drug Development. The principles name post-marketing among the life cycle phases where AI may be used and call for scheduled monitoring and periodic re-evaluation of AI performance.
The European Medicines Agency (EMA) has set out its position in writing. Its reflection paper on AI anticipates that AI and ML tools can support adverse event report management and signal detection, and that the marketing authorization holder remains responsible for validating, monitoring, and documenting model performance and for including AI and ML operations in its pharmacovigilance system.
That last point has a practical consequence for the pharmacovigilance system master file (PSMF), the document that describes how a company’s PV system operates. Once models run inside that system, teams need their versions, validation records, and change history documented and kept current. PSMF automation keeps that documentation current by capturing model changes as they happen rather than reconstructing them before an inspection.
Reporting deadlines remain unchanged by automation. Under EU legislation, as set out in Good Pharmacovigilance Practices (GVP) Module VI, serious valid ICSRs must be submitted within 15 days from the date of receipt and non-serious valid ICSRs within 90 days.[6] In the U.S., postmarketing ICSRs for human drugs, biologics, and drug- or biologic-led combination products submitted through FDA’s Electronic Submissions Gateway Next Generation (ESG NextGen) must use the International Council for Harmonisation (ICH) E2B(R3) data standards from October 1, 2026.[7] Structured, machine-generated case data makes both obligations easier to meet consistently.
Which Pharmacovigilance Decisions Should Stay With Human Reviewers?
The Council for International Organizations of Medical Sciences (CIOMS) published its Working Group XIV report on AI in pharmacovigilance on December 4, 2025. On the working group’s page, CIOMS describes AI agents as a way to relieve experts of repetitive PV tasks so they can focus on analyses that need their full expertise, such as differential diagnosis and causality assessment.
That framing matches how effective programs are designed. Automation handles volume and consistency. Safety physicians and PV scientists keep the decisions that carry regulatory and patient consequences: causality, final seriousness on ambiguous cases, signal validation, and benefit-risk conclusions. Systems that show reviewers why a case was classified a certain way make that oversight, and broader AI model governance, faster and easier to defend.
How Intuceo Approaches Pharmacovigilance Automation
Intuceo’s PhD-led teams build PV automation around the client’s existing safety systems and standard operating procedures. Engagements typically cover automated adverse event report classification using explainable AI, which produces an evidence-based rationale alongside each classification so reviewers can audit the output instead of rewriting it. They also extend to continuous post-market adverse event monitoring, PSMF optimization, and neural search through Intuceo-Ix to surface safety-relevant content across literature and internal documentation. For a Fortune 100 pharma and MD&D client, explainable adverse event detection increased complaint throughput, reduced expert review time, and supported timely FDA submittals.
Each model is scoped, validated, and documented for its specific task, with human checkpoints placed where the regulations and the client’s quality system require them.
Find where your safety workflow is losing time
Intuceo’s pharmacovigilance assessment maps your intake, coding, submission, and signal review steps, identifies which ones can be automated safely, and outlines the validation and documentation each change would need.
Frequently Asked Questions
1.What is pharmacovigilance automation?
Pharmacovigilance automation uses software, NLP, and ML to handle repetitive drug safety steps, including intake, validity checks, MedDRA coding, duplicate detection, narrative drafting, and signal scoring. Reviewers confirm the outputs and keep medical decisions.
2.Which pharmacovigilance tasks can AI automate?
AI can automate case intake and data extraction, seriousness prediction, MedDRA coding suggestions, duplicate matching, narrative drafting, E2B(R3) report building, literature and social media screening, and continuous signal scoring.
3.How does AI automate pharmacovigilance signal detection?
AI models score drug and event combinations continuously as new reports arrive, using features beyond report counts, such as label information and organ-specific data. In a study of historical Korean safety data for infliximab, ML models flagged four of five pre-specified adverse events before they were added to the drug label, and they outperformed standard disproportionality methods when applied to FDA data.[4] The output is a ranked list of candidate signals that safety physicians then validate.
4.What is the difference between traditional and AI-powered adverse event surveillance?
Traditional surveillance depends on people reading each report and on statistical screening run at fixed intervals. AI-powered surveillance processes every report on arrival, extracts and codes data automatically, and updates signal rankings continuously. Reviewers spend their time confirming outputs and making medical judgments rather than performing data entry.
5.Can AI replace human pharmacovigilance reviewers?
No. EMA places responsibility for validating and monitoring AI models on the marketing authorization holder,[5] and CIOMS describes AI as a way to free experts for causality assessment and similar analyses.[8] AI changes what reviewers spend their time on. Accountability for safety decisions stays with qualified people.
6.How does AI help meet FDA and EMA post-market safety reporting requirements?
Automated intake and seriousness prediction get serious cases in front of reviewers sooner, which protects the 15-day EU submission window for serious reports. Structured extraction also supports the E2B(R3) data standard that FDA now requires for postmarketing ICSRs submitted through ESG NextGen. In the EU, the AI components themselves must be validated, monitored, and documented within the PV system
